Will the FDA approve lorundrostat for hypertension?

• What pushes it up. Company’s public moves suggest confidence in an imminent hypertension approval (Endpoints News, tier 2)
• What pushes it up. NDA acceptance and a set PDUFA target date indicate FDA is proceeding toward a decision (hand‑verified tier 1)
• What pushes it down. Recent Phase 2 OSA trial failed, raising possible safety/efficacy concerns for the same molecule (hand‑verified tier 1)
• What pushes it down. Base‑rate for new‑mechanism drugs is only 64%, reflecting inherent uncertainty
• What would move this number most. The FDA’s final decision at the PDUFA date – whether it issues approval or a complete response letter.

• What pushes it up. NDA acceptance and scheduled PDUFA date indicate a review will occur, raising the likelihood of approval. [1]
• What pushes it down. No tier 1 or 2 evidence of approval or positive data for hypertension, and the mechanism is new with no prior approvals, lowering confidence. [4]
• What would move this number most. Whether the FDA will find the efficacy and safety data sufficient for approval; a rejection would drop the probability dramatically.

• What pushes it up. NDA acceptance and a PDUFA target date of 22 Dec 2026 indicate the FDA has moved the application forward (tier 2).
• What pushes it down. No hypertension efficacy data or safety signals have been reported; the mechanism is novel and has no prior approvals, lowering confidence in a favorable outcome (tier 2).
• What would move this number most. The availability and quality of hypertension trial data and the safety profile of lorundrostat will most influence the approval likelihood.

• What pushes it up. NDA acceptance and PDUFA target date of 22 Dec 2026 indicate the agency has reviewed the data and is proceeding to decision (tier 2).
• What pushes it down. No published data on hypertension efficacy or safety; the mechanism is novel with no prior approvals for this indication, raising uncertainty (tier 2).
• What would move this number most. The actual clinical and safety data for hypertension will most influence the outcome.

• What pushes it up. The FDA accepted the NDA for lorundrostat with a target PDUFA action date of December 22, 2026, supported by positive Phase 3 clinical trial data in hypertension [tier 2].
• What pushes it up. Mineralys Therapeutics has undertaken major financial and operational preparations ahead of the target action date, indicating strong readiness for launch [tier 2].
• What pushes it down. As an aldosterone synthase inhibitor, lorundrostat represents a novel mechanism of action not previously approved in the US for hypertension, introducing higher regulatory scrutiny [tier 1].
• What pushes it down. First-cycle approvals remain subject to manufacturing (CMC) or unexpected regulatory hurdles that frequently trigger Complete Response Letters [tier 3].
• What would move this number most. Whether any unforeseen manufacturing (CMC) issues or late-stage FDA requests delay the review or result in a Complete Response Letter before December 22, 2026.

• What pushes it up. Positive Phase 3 Launch-HT data reported in March 2026 supports the efficacy of lorundrostat for hypertension [2, 5].
• What pushes it up. AstraZeneca's May 2026 approval in the hypertension space validates the therapeutic landscape and potentially the aldosterone synthase inhibitor class [2, 4].
• What pushes it up. Mineralys' $200M expenditure to eliminate future royalties on lorundrostat indicates high internal confidence in the drug's approval and commercial success [4, 9].
• What pushes it up. The company is actively preparing for a commercial launch, as evidenced by its participation in major investor conferences [4, 6].
• What pushes it down. The resolution criterion is strict: any PDUFA extension or Complete Response Letter (CRL) results in a 'No' [Resolution].
• What pushes it down. There is a significant historical risk of CRLs due to non-clinical factors such as manufacturing (over 50%) or product quality (41%) [3, 11].
• What pushes it down. Lorundrostat failed a related Phase 2 trial in obstructive sleep apnea, which may indicate limitations in its broader clinical profile [1].
• What would move this number most. The primary uncertainty is the risk of a PDUFA date extension or a CRL due to manufacturing or quality issues, which are common causes for first-cycle failures even when clinical data is strong.

Reasons not recorded for this revision (detailed history has only been kept since recently).

Reasons not recorded for this revision (detailed history has only been kept since recently).